In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 276 to 300 of 399

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Pembrolizumab with chemotherapy with or without bevacizumab for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments ID6363	Technology appraisal guidance	TBC
Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861]	Technology appraisal guidance	TBC
Pembrolizumab with lenvatinib and chemotherapy for untreated advanced gastro-oesophageal junction cancer [TSID11861]	Technology appraisal guidance	TBC
Pembrolizumab with lenvatinib and chemotherapy for untreated metastatic squamous cell oesophageal cancer [TSID12096]	Technology appraisal guidance	TBC
Pembrolizumab with olaparib and chemoradiation for previously untreated limited-stage small-cell lung cancer [ID6412]	Technology appraisal guidance	TBC
Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]	Technology appraisal guidance	TBC
Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma [ID4044]	Technology appraisal guidance	TBC
Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell lung cancer [ID6149]	Technology appraisal guidance	TBC
Pembrolizumab–vibostolimab for untreated metastatic non-small-cell lung cancer [ID6365]	Technology appraisal guidance	TBC
Pembrolizumab–vibostolimab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6361]	Technology appraisal guidance	TBC
Perioperative care in adults	Quality standard	1 July 2026
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]	Technology appraisal guidance	TBC
PillCam COLON 2 for investigation of the colon through direct visualisation	Diagnostics guidance	TBC
Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269]	Technology appraisal guidance	29 January 2026
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]	Technology appraisal guidance	TBC
Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]	Technology appraisal guidance	TBC
Plozasiran for treating familial chylomicronaemia syndrome [ID6593]	Technology appraisal guidance	TBC
Polihexanide eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]	Technology appraisal guidance	28 January 2026
Polycystic ovary syndrome: assessment and management	NICE guideline	3 November 2026
Psoriasis: assessment and management (CG153)	NICE guideline	TBC
Pulmonary artery pressure technologies for remote monitoring of chronic heart failure	Diagnostics guidance	20 January 2026
Radium-223 dichloride with enzalutamide for treating asymptomatic or mildly symptomatic hormone-relapsed metastatic prostate cancer with bone metastases [ID6512]	Technology appraisal guidance	7 April 2027
Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over [TSID10642][ID6319]	Technology appraisal guidance	TBC
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]	Technology appraisal guidance	15 November 2017
Rehabilitation for chronic neurological disorders including acquired brain injury	NICE guideline	15 October 2025

Results per page

10
25
50
All